M Stetler Stevenson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
    M Stetler-Stevenson
    Laboratory of Pathology and the Biostatistics, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:979-87. 2001
  2. ncbi A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
    R A Messmann
    Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 6:1302-13. 2000
  3. ncbi Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
    R J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 345:241-7. 2001
  4. ncbi Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
    T Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Leukemia 21:169-74. 2007
  5. ncbi Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis
    L J Medeiros
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Arch Pathol Lab Med 117:279-83. 1993
  6. ncbi Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
    Y Saunthararajah
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 112:195-200. 2001

Collaborators

Detail Information

Publications6

  1. ncbi Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
    M Stetler-Stevenson
    Laboratory of Pathology and the Biostatistics, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:979-87. 2001
    ..It is concluded that flow cytometric immunophenotyping may help establish the diagnosis of MDS, especially when morphology and cytogenetics are indeterminate. (Blood. 2001;98:979-987)..
  2. ncbi A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
    R A Messmann
    Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 6:1302-13. 2000
    ....
  3. ncbi Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
    R J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 345:241-7. 2001
    ..We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is strongly expressed by leukemic hairy cells...
  4. ncbi Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
    T Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Leukemia 21:169-74. 2007
    ..Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases...
  5. ncbi Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis
    L J Medeiros
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Arch Pathol Lab Med 117:279-83. 1993
    ..Thus, we suggest that the lymphocytosis results from a poorly defined immunoregulatory disorder, related to the presence of thymoma, and perhaps secondary thymic hormone imbalance...
  6. ncbi Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
    Y Saunthararajah
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 112:195-200. 2001
    ..The lower response rate of MDS or T-LGL/MDS to immunosuppression, compared with T-LGL alone, may reflect the older age and intrinsic stem cell abnormalities in MDS and T-LGL/MDS patients...